Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05201027
Other study ID # AT ELANA 841P-BER-301-19
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date January 28, 2022
Est. completion date July 27, 2022

Study information

Verified date August 2022
Source Carl Zeiss Meditec AG
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Prospective, non-comparative, multicenter study on medical device with 6 months follow-up.


Recruitment information / eligibility

Status Terminated
Enrollment 52
Est. completion date July 27, 2022
Est. primary completion date July 27, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult patient of any gender; - Patient with clinically significant bilateral age-related cataracts with planned phacoemulsification cataract extraction and suitable for implantation of a posterior chamber trifocal intraocular lens as determined by investigator's medical judgement; - Projected postoperative corrected distance visual acuity (CDVA) better than 0.2 LogMAR as determined by investigator's medical judgement; - Preoperative keratometric (corneal) astigmatism =1.5 D; - Clear intraocular media other than cataract; - Requiring an IOL power within the available range of the investigational IOL (15.0 to +27.0 D, in 0.5 D increments); - Patient agrees to have surgery of the second eye performed between 1 day and 10 days after the surgery of the first eye. - Given written informed consent by patient; - Patient willing and able to comply with examination procedures and schedule for follow-up visits; Exclusion Criteria: - Presence of uncontrolled systemic disease that could increase the operative risk or confound the outcome including but not limited to diabetes mellitus, active cancer treatment, mental illness, dementia, immunocompromised, connective tissue disease, clinically significant atopic disease, etc.; - Ocular condition that may predispose patient to future complications, per investigator's medical judgement, including but not limited to severe dry eye, anterior segment pathology, glaucoma (uncontrolled despite intake of medication), macular degeneration; - Clinically significant corneal abnormalities, including corneal dystrophy (epithelial, stromal or endothelial dystrophy), irregularity, inflammation or oedema as per Investigator's medical judgement; conditions including but not limited to keratitis, keratoconjunctivitis, kerato uveitis, keratopathy, keratectasia; - Previous intraocular or corneal/refractive surgery that might confound the outcome of the investigation or increase the risk to the patient (including corneal transplants, removal of pterygium etc.); - Use of and foreseeable use of systemic medications that may confound the outcome or increase the risk to the patient per investigator's medical judgement (e.g., steroids, Tamsulosin Hydrochloride or other medications including anticholinergics or alpha-adrenergic blocking agents with similar side effects [e.g. small pupil/floppy iris syndrome], anti-metabolites, etc.); - Patients with diagnosed degenerative visual disorders (e.g. macular degeneration or other retinal disorders, optic nerve atrophy etc.) or any other pathologies of the eye that are predicted to cause future acuity loss to 0.2 LogMAR (CDVA) or worse; - Patients with conditions that increase the risk of zonular rupture during cataract extraction procedure that may affect the postoperative centration or tilt of the lens; - Patients with previous refractive surgery procedures, including but not limited to LASIK, limbal relaxing incision; - Planned concomitant ocular procedure during cataract surgery or within the next 6 months (e.g. glaucoma surgery including implantation of MIGS, astigmatic correction surgery, penetrating keratoplasty, laser-assisted in situ keratomileusis); - Patients who are expected to require retinal laser treatment within the next 6 months per investigator's medical judgement; - Amblyopia; - Rubella, congenital, traumatic or complicated cataracts; - History of or current anterior or posterior segment inflammation, including but not limited to iritis or uveitis; - Microphthalmos or macrophthalmos; - Iris defects (e.g. aniridia); - Optic nerve atrophy; - Pseudoexfoliation; - Keratoconus or irregular astigmatism; - Inability to measure keratometry or biometry (including but not limited to cataract density, patient unable to focus for longer time etc.); - Pathologic miosis; - Pregnant, lactating during the course of the investigation, or another condition with associated fluctuation of hormones that could lead to refractive changes; - Patient whose freedom is impaired by administrative or legal order; - Concurrent participation in another drug or device investigation that could confound the outcome of this investigation.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
trifocal intraocular lens
cataract extraction and implantation of a posterior chamber trifocal intraocular lens

Locations

Country Name City State
El Salvador Clínica Quesada San Salvador

Sponsors (1)

Lead Sponsor Collaborator
Carl Zeiss Meditec AG

Country where clinical trial is conducted

El Salvador, 

Outcome

Type Measure Description Time frame Safety issue
Primary Optimization of the IOL constant Optimization of the calculated IOL constant with regression analysis by utilizing the following data measured during the study: Corneal radii, axial length, anterior chamber depth, IOL power, target refraction, manifest refraction and refraction distance 6 months
See also
  Status Clinical Trial Phase
Completed NCT04998409 - Evaluation of a Spherical Hydrophilic Acrylic Intraocular Lens
Completed NCT04252716 - VISPER: Randomised Comparison of Two OVDs in Cataract Surgery
Recruiting NCT05110222 - Cataract Lens Hardness Based on Phaco Tip Resistance
Recruiting NCT04266847 - Prospective Clinical Study of Preoperative and Postoperative Unilateral Mild Cataract Patients N/A
Recruiting NCT04175951 - Tecnis Eyhance Versus Rayner RayOne Study N/A
Recruiting NCT04572334 - Eyhance Autorefraction Study N/A
Completed NCT04140383 - Cataract Surgery In Patients With Advanced Age
Active, not recruiting NCT04570579 - Impact of a Novel Extended Depth of Focus Intraocular Lens on Visual and Lifestyle Enhancement
Completed NCT05347615 - Achieving Hybrid Monovision By Paring Monofocal And EDOF Lens Technology
Recruiting NCT05129566 - Evaluation of Axial Stability of Two Models of Intraocular Lenses in Patients With an Eye Length More Than 26 mm N/A
Recruiting NCT05148507 - Optimization of the Ocular Surface Prior to Cataract Surgery Using PROKERA N/A
Completed NCT04655274 - Comparision of Visual Outcomes and Patient Satisfaction Between Two Diffractive Trifocal Intraocular Lenses
Completed NCT04255706 - Repeatability in Measurements of Two ssOCT and One OLCR Biometer N/A
Completed NCT05287269 - Ocular Coherence Tomography During Cataract Assessment
Completed NCT04545671 - Evaluation of a Trifocal Lens
Completed NCT04580550 - Axial Length Variability N/A
Recruiting NCT04265846 - Prospective Clinical Study of Different Intraocular Lens Implantation Designed for the Correction of Presbyopia
Completed NCT03970525 - Venturi and Peristaltic Based Phacoemulsification in Femtosecond Laser Cataract Surgery
Completed NCT04333056 - Comparison Between Two Ss-OCT Biometry
Completed NCT05578339 - Predicting the Lens Capsular Bag Size Using Pre-operative Biometry N/A